as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹495.4
Change
-6.35 (-1.27%)
Open
₹501.75
Prev. Close
₹501.75
Day High
₹514.1
Day Low
₹487.0
Volume Analysis
Traded
153,543
Delivered
47,036
Delivery %
30.63%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (1)
- •Low return on equity (4.88%)
Opportunities (2)
- •Strong 3-year EPS growth (39.5%)
- •Strong 3-year revenue growth (57.8%)
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹537.76 | ₹525.93 | ₹510.66 | ₹498.83 | ₹483.56 | ₹471.73 | ₹456.46 |
| Fibonacci | ₹525.93 | ₹515.58 | ₹509.18 | ₹498.83 | ₹488.48 | ₹482.08 | ₹471.73 |
| Camarilla | ₹502.85 | ₹500.37 | ₹497.88 | ₹498.83 | ₹492.92 | ₹490.43 | ₹487.95 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
—
1 Week
-1.34%
1 Month
+5.95%
3 Months
-8.4%
6 Months
+1.79%
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹90.22
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
2.89%
Net margin 3.74% × asset turnover 0.29x × equity multiplier 2.66x
Company Overview
Sector
Healthcare
Market Cap
₹2,189 Cr
P/E (TTM)
87.8
ROE
4.88%
Book Value
₹112.0
Face Value
₹5.0
Source: Screener.in (Consolidated figures) — data as of 20 Nov 2026. Not investment advice.
TopFund Analysis
Sai Parenterals Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 50/100. The strongest factor is Growth (100/100), while Institutional Ownership (18/100) is the weakest area to weigh before deciding. Notably: Low return on equity (4.88%). FII holding has been falling.
TopFund Score — Fundamentals Quality
50/100 — AverageData confidence: 78/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Debtor days have improved from 253 to 173 days.
- −Stock is trading at 4.41 times its book value
- −Though the company is reporting repeated profits, it is not paying out dividend
- −Company has low interest coverage ratio.
- −Tax rate seems low
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Subsidiary SP Analytics to acquire majority stake in Bion Therapeutics’ prescription business by month-end.
Call conducted on Monday the 2nd day of November, 2026.
Un-audited financial results for the quarter and half-year ended 30th September, 2026.
Audio recording of Q2 FY2027 earnings call held on 2 November 2026 is now available.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|
| Sales + | 33 | 54 | 96 | 198 | 179 | 195 |
| Expenses + | 29 | 42 | 100 | 172 | 155 | 155 |
| Operating Profit | 5 | 11 | -4 | 26 | 24 | 40 |
| OPM % | 14.0% | 21.0% | -3.7% | 13.0% | 13.0% | 21.0% |
| Other Income + | 1 | 1 | 3 | 3 | 4 | 4 |
| Interest | 2 | 2 | 5 | 8 | 9 | 9 |
| Depreciation | 1 | 1 | 6 | 8 | 8 | 25 |
| Profit before tax | 2 | 9 | -12 | 12 | 10 | 10 |
| Tax % | 30.0% | 31.0% | -43.0% | -6.0% | 19.0% | -6.0% |
| Net Profit + | 1 | 6 | -7 | 13 | 8 | 11 |
| EPS in Rs | 0 | 2 | -2 | 3 | 2 | 2 |
| Raw PDF | — | — | — | — | — | — |
| YoY Sales growth | — | — | — | — | 435 | 264 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|
| Sales + | 97 | 154 | 163 | 381 | 668 |
| Expenses + | 78 | 122 | 124 | 342 | 581 |
| Operating Profit | 19 | 32 | 39 | 39 | 86 |
| OPM % | 19.0% | 21.0% | 24.0% | 10.0% | 13.0% |
| Other Income + | 0 | 1 | 1 | 9 | 13 |
| Interest | 6 | 11 | 12 | 19 | 32 |
| Depreciation | 6 | 9 | 8 | 17 | 47 |
| Profit before tax | 7 | 13 | 20 | 12 | 20 |
| Tax % | 40.0% | 33.0% | 28.0% | -20.0% | — |
| Net Profit + | 4 | 8 | 14 | 14 | 25 |
| EPS in Rs | 1 | 2 | 4 | 3 | 5 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Sales growth | — | 59 | 6 | 134 | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|
| Reserves | 24 | 61 | 80 | 469 | 184 |
| Borrowings + | 69 | 119 | 94 | 469 | 374 |
| Other Liabilities + | 34 | 75 | 85 | 465 | 450 |
| Total Liabilities | 134 | 268 | 272 | 1,424 | 1,320 |
| Fixed Assets + | 44 | 70 | 53 | 364 | 377 |
| CWIP | 2 | 0 | 0 | 212 | 269 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 88 | 198 | 219 | 848 | 674 |
| Total Assets | 134 | 268 | 272 | 1,424 | 1,320 |
| Equity Capital | 7 | 13 | 13 | 22 | 312 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from Operating Activity + | -13 | -30 | 33 | 93 |
| Cash from Investing Activity + | -19 | -46 | 0 | -274 |
| Cash from Financing Activity + | 24 | 79 | -36 | 596 |
| Net Cash Flow | -8 | 2 | -2 | 415 |
| Free Cash Flow | -30 | -72 | 41 | -184 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -54 | -94 | 86 | 253 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|
| Public | 30.25% | 36.29% | 38.16% |
| Promoters | 51.16% | 51.16% | 51.16% |
| FII | 5.73% | 4.03% | 2.85% |
| DII | 12.86% | 8.52% | 7.83% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Sai Parenterals Limited (this stock) | 2,189 | 87.8 | 4.42 | 4.88% |
| Dishman Carbo Amcis Ltd | 2,183 | 151.0 | 0.33 | 1.58% |
| Sakar Healthcare Limited | 2,172 | 50.7 | 6.26 | 9.99% |
| Panacea Biotec Ltd | 2,171 | — | 2.6 | -2.42% |
| Vimta Labs Limited | 2,230 | 36.7 | 6.46 | 13.5% |
| Indoco Remedies Ltd. | 2,079 | — | 2.03 | -9.36% |
| Windlas Biotech Limited | 2,067 | 31.1 | 3.64 | 12.2% |
Which Mutual Funds Hold Sai Parenterals Limited?
Frequently Asked Questions about Sai Parenterals Limited
Sai Parenterals Limited (SAIPARENT) closed at ₹495.4 on NSE on 19 November 2026, down 6.35 (1.27%) from the previous close.
Sai Parenterals Limited trades on the NSE (National Stock Exchange of India) under the symbol SAIPARENT.
Sai Parenterals Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 87.8.
Sai Parenterals Limited has a dividend yield of 0.0%.
Sai Parenterals Limited's 52-week high is ₹706.0 and its 52-week low is ₹400.0.
Sai Parenterals Limited has a market capitalisation of ₹2,189 crore.
Sai Parenterals Limited has a TopFund Quality Score of 50/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Sai Parenterals Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.